drugset
drugset / Trial / NCT06879327

Infant Malaria Vaccine Schedule Optimization

NCT06879327 ↗

Phase 2 Recruiting 964 enrolled PATH Agilis · collabCytespace · collabMCT-CRO · collabPharmassist Ltd · collabSerum Institute of India Pvt. Ltd. · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

The aim of this study is to identify an optimal infant vaccine schedule for a malaria vaccine which is better aligned with the timing of other vaccine interventions.

Timeline

Start
2025-05-30
Primary completion
2027-09-27
Completion
2027-09-27

Drugs

EvaluationDrugModalityDoseRoute
Subject R21 Matrix-M Vaccine 0.5 ml Intramuscular
Background Hexavalent vaccine Vaccine 0.5 ml Intramuscular
Background Measles and Rubella Vaccine Vaccine 0.5 ml Subcutaneous
Background Meningococcal (A, C, Y, W, X) polysaccharide conjugate vaccine Vaccine 0.5 ml Intramuscular
Background Pneumosil Vaccine 0.5 ml Intramuscular
Background Rotavirus, Live Attenuated (Oral) Vaccine Vaccine 2 ml Oral
Background Typhoid Conjugate vaccine Vaccine — —
Background Yellow Fever Vaccine Vaccine — —

Indications

malaria